Name: The Trajectory of Discovery: What Determines the Rate and Direction of Medical Progress? (en Inglés)
Price: 186051.00 COP
Availability: InStock
Author: Khurana, Mark P.
ISBN: 9781009354431

portada The Trajectory of Discovery: What Determines the Rate and Direction of Medical Progress? (en Inglés)

Formato

Libro Físico

Autor

Mark P. Khurana

Editorial

Cambridge University Press

Idioma

Inglés

N° páginas

192

Encuadernación

Tapa Blanda

ISBN13

9781009354431

N° edición

Categorías

Cuestiones generales de la medicina

The Trajectory of Discovery: What Determines the Rate and Direction of Medical Progress? (en Inglés)

Mark P. Khurana (Autor) · Cambridge University Press · Tapa Blanda

Libro Nuevo

$ 186.051

$ 310.085

Ahorras: $ 124.034

40% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Viernes 14 de Junio y el Martes 25 de Junio.

Lo recibirás en cualquier lugar de Colombia entre 1 y 5 días hábiles luego del envío.

Reseña del libro "The Trajectory of Discovery: What Determines the Rate and Direction of Medical Progress? (en Inglés)"

Medical research works in trajectories. Scientists and researchers must choose to pursue certain scientific pathways and omit others, limited by resources, attention, and time. The trajectory of medical progress is therefore characterized by two crucial characteristics: rate and direction. These two components form the foundation for this book - what are the forces that determine the rate and direction of progress in medicine? This book brings together the worlds of scientific policy, economics, sociology, philosophy, and innovation to describe why the world of medical research looks the way it does. The book also addresses fundamental contemporary issues in medicine, how they influence progress, and how we might improve medical research going forward. The contemporary issues discussed include: flawed incentive structures, a concentration of power and resources among few actors and disease groups, the potential distortionary effects of lobbying by different scientific actors, and missing novelty in drug development.